Stock Region Watchlist
Quantum Leaps & My Watchlist 👀
Quantum Leaps & Watchlist 👀
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Hey everyone,
Before we dive into this week’s watchlist, a quick but important reminder: I am not a financial advisor and this is not financial advice. The content in this newsletter is for informational and entertainment purposes only. Please do your own research and consult with a professional before making any investment decisions. Trading involves risk, and you should never invest more than you can afford to lose.
Now, let’s get to the good stuff. It’s been an interesting week, and I’ve got my eye on a few companies that are making some serious moves—or at least have the potential to.
Here’s what’s on my radar for Thursday, October 23, 2025:
IonQ (IONQ): The Quantum Wildcard
Honestly, quantum computing still feels a bit like science fiction to me, but IonQ is making it very real. With a staggering 269% return over the last year, it’s impossible to ignore. Their recent partnership with AstraZeneca to speed up drug discovery is exactly the kind of real-world application I love to see. This isn’t just theory; it’s potentially world-changing tech. I’m incredibly optimistic about their long-term story, even if the short-term ride is bumpy. It feels like getting in on the early days of the internet. High risk? Absolutely. But the potential reward is just massive.
Molina Healthcare (MOH): The Contrarian Play
Molina got absolutely hammered after its Q3 earnings. The stock plunged, and the guidance cut didn’t help. So why is it on my list? Because I’m a sucker for a potential comeback story. Despite the bad news, revenue is still up 11% year-over-year. They’re growing, but they have some serious costs to get under control. This is a classic “don’t catch a falling knife” scenario, but I’m watching it closely. If it can hold above $154 and show signs of life by breaking $160, it could be an interesting recovery play. I’m cautiously curious here.
Tesla (TSLA): The Undeniable Force
What can I say about Tesla that hasn’t already been said? It’s the king of the EV hill, and its latest earnings report shows it’s not slowing down. Analysts keep raising their price targets, and it’s hard to argue with them. While some people get hung up on the day-to-day drama, I try to focus on the bigger picture: they are dominating a market that is only going to get bigger. I’m watching for a solid break above $428.28 to confirm the next leg up. It remains a core holding in my long-term growth perspective.
Hasbro (HAS): The Holiday Hopeful
Hasbro is more than just toys; it’s a nostalgia machine. From board games to action figures, they own a piece of so many childhoods. My interest right now is purely on their shift into digital gaming and entertainment. That’s where the real growth could be. The upcoming holiday season will be a huge test. Will consumers open their wallets for toys and games? I’m watching this one to get a read on consumer sentiment. If it can push past $75, it could have a nice run into the end of the year.
Beyond Meat (BYND): The Plant-Based Gamble
I have a real love-hate relationship with Beyond Meat. I love the mission and the product, but the stock has been just brutal. It feels like it’s in a perpetual state of “prove it.” Still, the demand for sustainable food isn’t going away. They need to show they can capture more of the market and, more importantly, turn a profit. I’m looking for a spark—any spark. A breakout above $3.07 could signal that maybe, just maybe, the bottom is in. This is a high-risk, speculative watch for me.
IBM (IBM): The Old Dog With New Tricks
Don’t sleep on Big Blue. IBM is quietly making some very impressive moves in AI and quantum computing, positioning itself as a direct competitor to some of the market’s darlings. Their recent strong earnings, powered by hybrid cloud solutions, prove they can still innovate and execute. With the government throwing money at quantum development, IBM is perfectly placed to benefit. I’m watching for a move above $269.43 as a sign that the market is finally giving this tech giant the credit it deserves.
That’s all for this week! Keep your eyes on the charts and your emotions in check.
Happy trading,
The Stock Region Team
Disclaimer: All content provided in this newsletter is for informational and entertainment purposes only. The author is not a licensed financial advisor. The information presented is not intended to be and does not constitute financial advice, investment advice, trading advice, or any other advice. You should not make any decision, financial, investment, trading or otherwise, based on any of the information presented in this newsletter without undertaking independent due diligence and consultation with a professional broker or financial advisor. You understand that you are using any and all information available on or through this newsletter at your own risk.
The AstraZeneca partnership is actualy a bigger deal than most people realize. Drug discovery is one of those use cases where quantum computing can deliver value well before we get to fault tolerant systems. The 269% return is obviously wild, but you're right that it's more about the long term story than the short term volatility. I do think the early internet comparison is fair in terms of potential impact, though the timeline to profitability is probably longer than most investors are expecting. What's interesting is how IonQ is positioning themselves across multiple verticals (pharma, materials science, finance) rather than going all in on one sector. The risks are huge here but the optionality is pretty atractive. If they can maintane their lead in gate fidelity and scale their systems as planned, the market cap could look cheap in retrospect. Good to see quantum getting more mainstream coverage!